<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947216</url>
  </required_header>
  <id_info>
    <org_study_id>6398</org_study_id>
    <nct_id>NCT03947216</nct_id>
  </id_info>
  <brief_title>Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.</brief_title>
  <acronym>PIMPARK</acronym>
  <official_title>Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NS-PARK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EUCLID</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>F-CRIN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no consensus on the treatment of Impulse Control Disorder (ICD) in Parkinson Disease
      (PD) though it is recommended to reduce the dosage of dopamine agonists (DA).

      Reduction of DA frequently leads to a worsening of motor signs (parkinsonism or dyskinesias
      due to the concomitant increase of levodopa doses) and non-motor signs with the appearance of
      a DA withdrawal syndrome (DAWS).

      Chronic stimulation of the sub-thalamic nuclei may reduce ICD but is restricted to a minority
      of patients and cases of new-onset ICD symptoms post stimulation have been reported. The
      benefit of amantadine in pathological gambling is controversial and the efficacy of clozapine
      has been reported in a few cases but with serious safety limitations. Very recently,
      naltrexone did not significantly improve ICD.

      Thus, an efficacious and safe treatment of ICD in PD remains an unmet need for clinical
      practice.

      Recently, it has been reported that pimavanserin, a selective serotonin 5-HT2A inverse
      agonist with a satisfactory safety profile without motor side effects, was efficient in
      improving psychosis, insomnia and day-time sleep in PD.

      Pimavanserin, marketed under the tradename NUPLAZID® was approved in 2016 by the U.S. Food
      and Drug Administration (FDA) for the treatment of hallucinations and delusions associated
      with Parkinson's disease psychosis.

      The link between serotonin and ICD has been well established, since the enhancement of 5HT2A
      receptors stimulation is associated to ICD, since serotonin modulates mesolimbic dopaminergic
      reward system transmission and given that serotonin neurotransmission is increased during
      chronic intake of dopamine agonist such as pramipexole which is well-known to induce ICD in
      PD patients. Thus, there is a large body of evidence suggesting that the decrease of the
      5HT2A activity could be efficient in reducing ICD in PD. This further supports the concept of
      testing the efficacy of pimavanserin (a selective 5HT2A inverse agonist) for treating ICD in
      PD. Our aim is to conduct a study evaluating the efficacy and safety of pimavanserin on ICD
      in PD.

      This clinical trial is conducted with the support of the French NS-Park/FCRIN (French
      Clinical Research Infrastructure Network) network.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ICD (Impulsive Control Disorders) severity after 8 weeks of treatment evaluated by QUestionnaire for Impulse-compulsive disorder in Parkinson's disease Rating Scale (QUIP-RS).</measure>
    <time_frame>at day 0 and week 8</time_frame>
    <description>The primary endpoint of this study will be assessed in both arms using the total form of QUIP-RS.
QUIP-RS has 4 primary questions (pertaining to commonly reported thoughts, urges/desires, and behaviors associated with ICDs), each applied to the 4 ICDs (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). It uses a 5-point Likert scale (score 0-4 for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16 and the total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112, with a higher score indicating greater severity (ie, frequency) of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change SCale for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP) score after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>The SCOPA-SLEEP is a specific Parkinson's disease rating scale for assessing nighttime sleep (NS) problems and daytime sleepiness (DS) in the past month. The NS subscale has 5 items, scored from 0 (not at all) to 3 (a lot). The DS subscale is composed of 6 items with response options ranging from 0 (never) to 3 (often) with a higher total score indicating greater severity of sleep problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Movement Disorders Society-sponsored Unified Parkinson's Disease Rating scale (MDS-UPDRS) scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease. The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily Living; II: Motor Experiences of Daily Living; III: Motor Examination; IV: Motor Complications. The four parts contains 64 items which are each rated on a scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Negative changes from baseline values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60 with higher MADRS score indicating more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ardouin's scale scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>The Ardouin's scale is a validated instrument using a structured and standardised interview composed of 21 items specifically designed to assess mood and behaviour with a view to quantifying changes related to Parkinson's Disease, to dopaminergic medication, and to non-motor fluctuations. Each item is scored from 0 (absent) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the rate of Clinical Global Impression Severity (CGIS) scale after 4, 8 and 16 weeks of treatment</measure>
    <time_frame>At day 0, week 4, week 8 and week 16</time_frame>
    <description>Severity of PD will be assessed in both arms using CGIS scale: the CGI-S is a 7-point scale that requires the rating of the severity of the patient's illness at the time of assessment. Possible ratings are: 1: Normal, not at all ill; 2: Borderline mentally ill; 3: Mildly ill; 4: Moderately ill ; 5: Markedly ill; 6: Severely ill; 7: Among the most extremely ill patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ICD (Impulsive Control Disorders) severity after 4 weeks of treatment evaluated by QUIP-RS.</measure>
    <time_frame>At day 0 and week 4</time_frame>
    <description>Global functioning and severity of the disease will be assessed in both arms by QUIP-RS has 4 primary questions each applied to the 4 ICDs and 3 related disorders It uses a 5-point Likert scale and a higher score indicating greater severity (ie, frequency) of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life measured by Parkinson's Disease Questionnaire (PDQ-39) scores after 4 and 8 weeks of treatment</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>Functioning and well-being of patients during the preceding month will be assessed in both arms by 39 questions of the self-administered Parkinson's Disease Questionnaire (PQD-39). Each question is scored from 0 (never) to 4 (always), the higher score indicating higher impact of illness in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Zarit scale scores after 4 and 8 weeks of treatment for caregivers</measure>
    <time_frame>At day 0, week 4 and week 8</time_frame>
    <description>The burden of the patient's functional and behavioural worsening and to home care will be assessed to the caregiver in both arms by the Zarit Burden scale. It is composed of 22 items to measure the magnitude of the burden experienced by the caregiver. Each item is scored from 0 (never) to 4 (almost always). With a higher score indicating a greater load suffered by the caregiver.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total number of adverse events and serious adverse events</measure>
    <time_frame>At week 16</time_frame>
    <description>Open-ended questionnaire will be used in both arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active drug: pimavanserin 17mg (2 strength tablets)</intervention_name>
    <description>Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: 2 tablets containing same excipients except active compound</intervention_name>
    <description>Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of severity of ICD (impulse control disorders)</intervention_name>
    <description>Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors</intervention_name>
    <description>Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of quality of life</intervention_name>
    <description>Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of depression</intervention_name>
    <description>Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of cognition</intervention_name>
    <description>Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment of severity of Parkinson Disease</intervention_name>
    <description>Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood analysis</intervention_name>
    <description>Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac monitoring</intervention_name>
    <description>Electrocardiogram will be realized at day 0, 28 and 56.</description>
    <arm_group_label>PIMAVANSERIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with PD according to the UKPDSBB (UK Parkinson's Disease Society Brain Bank)
             criteria for at least 1 year before randomization

          2. Patient, man or woman, aged from 35 to 75 years old

          3. Patient with moderately severe ICD defined as: a combined ICD total score (defined as
             the sum of the 4 ICD sub-scores (pathological gambling + buying + hypersexuality +
             eating)) 10 or, at least one of the 4 ICD sub-scores in the following range:

               1. &quot;pathological gambling&quot; sub-score from 6 to 12 (included),

               2. &quot;buying&quot; sub-score from 8 to 12 (included),

               3. &quot;hypersexuality&quot; sub-score from 8 to 12,

               4. &quot;eating&quot; sub-score from 7 to 12 (included) The use of &quot;lower&quot; margins will
                  guarantee that the patients will present with behavioral disturbances severe
                  enough to justify pimavanserin treatment. On the other hand, the use of &quot;upper&quot;
                  margins will guarantee that the patients included in the trial will not suffer
                  from ICD severe enough to question ethically the use of placebo during the 8
                  weeks of the treatment

          4. ICD onset after PD onset and after initiation of dopaminergic drugs

          5. Patient treated by dopaminergic drugs for at least 3 months before randomization

          6. Patient treated by a stable regimen of levodopa, dopamine agonists, COMT
             (Catechol-O-MethylTransferase) and MAOB (Monoamine oxidase B) inhibitors, amantadine,
             anticholinergic, antidepressant and benzodiazepine for at least 1 month before the
             randomization and be willing to remain on the same doses throughout the course of
             their participation in the trial

          7. Patient with health insurance

          8. Patient/ guardian / curator who sign the written informed consent

          9. For women of childbearing potential, use of an effective contraception method* for at
             least 1 month prior to randomization until 8 weeks after the last dose of study drug
             administration. Women who do not have an effective contraception* must : have had her
             last natural menstruation ≥24 months prior to the selection visit, or have been
             surgically sterilized prior to the selection visit, or have had a hysterectomy prior
             to the selection visit.

        Exclusion Criteria:

          1. Patient suffering from another parkinsonian syndrome (multiple system atrophy,
             progressive supranuclear palsy, Lewy body dementia, corticobasal degeneration)

          2. Patient who have a known hypersensitivity to the study treatment, based on known
             allergies to drugs of the same class

          3. Stroke, uncontrolled serious medical illness, myocardial infarction, congestive heart
             failure, cardiac function disorders, within 6 months before randomization

          4. Patient with history of long QT syndrome

          5. Patient with long QT interval detected with ECG at inclusion visit (&gt; 450 ms)

          6. Patient treated with antipsychotic drugs during the last three months before
             randomization.

          7. Patient treated with concomitant medications leading to torsade de pointes (TdP)
             (please refer to medications list with known risks of TdP on appendix XVII.5.10 and
             check website https://crediblemeds.org/index.php/tools/ for the most up-to-date
             information

          8. Patient with hydro-electrolytic troubles, particularly hypokaliemia or hypocalcemia
             not corrected, at inclusion visit

          9. Patient treated with a strong inhibitor of CYP3A4: azole antifungals, rotease
             inhibitors, macrolides, without discontinuation ≥ 5 half-lives before randomization

         10. Patient treated with medicinal plants interacting with CYP3A4 (Echinacea (E.purpurea,
             E.angustifolia and E.pallida), Piperina, Artemisia, St. John's Wort et Ginkgo

         11. Patient with Montreal Cognitive Assessment (MoCA) score &lt; 20 (to exclude patients
             likely with dementia) at inclusion visit

         12. Patient suffering from severe depression or marked suicidal thoughts (score &gt; 3 on the
             suicidal thoughts item of the MADRS) at inclusion visit

         13. History of Deep Brain Stimulation (DBS) within the past year before randomization

         14. Patient suffering from a cancer

         15. Patient suffering from severe renal impairment define as Creatinie clairance CrCL&lt;30
             mL/min, Cockcroft-Gault at inclusion visit

         16. Clinically significant hepatic impairment

         17. Current participation in another research involving human beings of category 1 or 2

         18. Patient with language barriers precluding adequate understanding or co-operation or
             who, in the opinion of the investigator, should not participate in the trial

         19. Treatment with an investigational treatment within 30 days prior to randomization

         20. Woman pregnant, nursing or of childbearing potential age without effective
             contraception methods or intends to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu ANHEIM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu ANHEIM, MD</last_name>
    <phone>+33 3 88 12 85 35</phone>
    <email>mathieu.anheim@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier RASCOL, MD</last_name>
    <phone>+33 5 61 14 59 62</phone>
    <email>olivier.rascol@univ-tlse3.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson CHU d'Amien, Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre KRYSTKOWIAK, MD</last_name>
      <phone>3 3 22 66 82 40</phone>
      <email>krystkowiak.pierre@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre KRYSTKOWIAK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE C, Unité mouvement anormaux/Centre expert Parkinson, CHU de Lyon, Hopital neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane THOBOIS, MD</last_name>
      <phone>+33 4 72 35 72 1</phone>
      <email>stephane.thobois@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Stephane THOBOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson CHU Clermont-Ferrand, Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck DURIF, MD</last_name>
      <phone>33 4 73 75 22 00</phone>
      <email>fdurif@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Franck DURIF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, Hopital Henri Montdor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe REMY, MD</last_name>
      <phone>+33 1 49 81 43 53</phone>
      <email>neuro-philippe.remy@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe REMY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie FRAIX, MD</last_name>
      <phone>+33 4 76 76 94 52</phone>
      <email>vfraix@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie FRAIX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, CHU de Lille, Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc DEFEBVRE, MD</last_name>
      <phone>+33 3 20 44 67 30</phone>
      <email>Luc.DEFEBVRE@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Luc DEFEBVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic TORNY, MD</last_name>
      <phone>+33 5 55 05 65 60</phone>
      <email>frederic.torny@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Frederic Torny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe AZULAY, MD</last_name>
      <phone>+33 4 91 38 43 33</phone>
      <email>Jean-philippe.AZULAY@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe AZULAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Nantes, Hopital Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiphaine ROUAUD, MD</last_name>
      <phone>+33 2 40 16 52 86</phone>
      <email>Tiphaine.Rouaud@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Tiphaine ROUAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE Centre Expert Parkinson Hopital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe CORVOL, MD</last_name>
      <phone>+33 1 42 16 57 66</phone>
      <email>jean-christophe.corvol@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe CORVOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Inverstigation Clinique, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Luc HOUETO, MD</last_name>
      <phone>+33 5 49 44 44 46</phone>
      <email>j.l.houeto@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc HOUETO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, CHU de REIMS</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DOE DE MAINDREVILLE, MD</last_name>
      <email>adoedemaindreville@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DOE DE MAINDREVILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rennes, Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie DRAPIER, MD</last_name>
      <phone>+33 2 99 28 42 93</phone>
      <email>Sophie.Drapier@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie DRAPIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rouen, Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David MALTETE, MD</last_name>
      <phone>+33 2 32 88 87 40</phone>
      <email>david.maltete@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>David MALTETE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE Unité de Mouvements Anormaux/Centre expert Parkinson, CHU de Strasbourg, Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu ANHEIM, MD</last_name>
      <phone>+33 3 88 12 85 35</phone>
      <email>mathieu.anheim@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu ANHEIM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Toulouse, Hopital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier RASCOL, MD</last_name>
      <phone>+33 5 61 14 59 62</phone>
      <email>olivier.rascol@univ-tlse3.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier RASCOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>impulse control disorders</keyword>
  <keyword>pimavanserin</keyword>
  <keyword>Serotoninergic 5-HT2A inverse agonist</keyword>
  <keyword>Dopamine agonist</keyword>
  <keyword>Behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Disruptive, Impulse Control, and Conduct Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

